logo
Plus   Neg
Share
Email

ViiV : 2-drug Regimen Of Dolutegravir Plus Lamivudine Effective To Control HIV-1

ViiV Healthcare, a majority-owned by GlaxoSmithKline (GSK.L,GSK), with Pfizer Inc. and Shionogi Limited as shareholders, said Wednesday that late-stage TANGO study met primary endpoint, showing the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen.

Kimberly Smith,Head of Global Research & Medical Strategy at ViiV Healthcare, said, "When we developed the TANGO study, we asked if virally suppressed people living with HIV could reduce the number of medicines in their HIV treatment regimen while maintaining viral suppression. These Week 48 data clearly indicate that they can - individuals who are already on treatment can maintain viral suppression if they switch from a 3-drug, TAF-containing regimen to a 2-drug regimen of dolutegravir plus lamivudine."

The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate or TAF-containing regimen of at least three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen or 2DR of dolutegravir plus lamivudine in a fixed dose combination, compared to continuing the TAF-containing regimen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford plans to bring back the Bronco as a dedicated off-road brand when it launches an all-new 4x4 SUV lineup on July 13. The automaker said it will introduce an all-new Bronco brand under the tagline, "Built Wild". The new lineup includes two-door and four-door models of the Bronco as well as the Bronco Sport compact SUV. J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.
Follow RTT